Spyre Therapeutics, Inc.
SYRE
$103.63
$1.781.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 13.49% | 14.12% | 25.39% | 30.68% | -11.20% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -160.67% | -102.25% | -114.72% | -124.78% | -36.83% |
| Change in Net Operating Assets | -144.12% | 40.27% | -30.88% | 141.46% | 132.51% |
| Cash from Operations | -35.52% | -9.28% | -7.52% | -7.03% | 1.44% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -848.97% | 65.04% | 59.39% | 69.45% | 86.36% |
| Cash from Investing | -848.97% | 65.04% | 59.39% | 69.45% | 86.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 225.73% | 36.21% | 28.88% | 121.18% | 167.13% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -100.00% | -100.00% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | 98.28% |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -5,629.46% | -976.95% | -188.45% | 23.84% | 93.08% |
| Cash from Financing | 214.76% | 34.45% | -24.79% | -36.43% | -26.07% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -150.00% | 133.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 121.99% | 127.14% | 96.29% | 67.11% | 118.93% |